Cell line · CVCL_1559
NCI-H358
Cancer cell line, Homo sapiens. Minimally invasive lung adenocarcinoma. 138 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H358. Cell lines, record CVCL_1559. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1559
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H358
- Accession
- CVCL_1559
- RRID
- RRID:CVCL_1559
- Synonyms
- H358, H-358, NCIH358
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- Age unspecified
- Category
- Cancer cell line
- Diseases
- Minimally invasive lung adenocarcinoma (NCIt C2923)
- Derived from
- Lung (in situ)
- Cell type
- Club cell
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | NCI-H358 and NCI-H358M (Cellosaurus=CVCL_JA53) could be identical. |
Source Cellosaurus
Papers138
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2. | J Med Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 138
See all 138 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HyCyte NCI-H358 KO-hGALNT14 | CVCL_F4J1 | Cell lines | |
| Derived from it | HyCyte NCI-H358 stable cell line for hKRAS overexpression | CVCL_F4W3 | Cell lines | |
| Derived from it | NCI-H358M | CVCL_JA53 | Cell lines | |
| Derived from it | NCI-H358a | CVCL_VK07 | Cell lines |
Cell banks8
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5807 | ATCC | |
| AddexBio | C0016016/4968 | Cellosaurus | |
| CLS | 300430 | CLS | |
| ECACC | 95111733 | ECACC | |
| Hysigen | TCH-C284 | Hysigen | |
| KCLB | 25807 | KCLB | |
| KCLB | 90358 | KCLB | |
| NCI-DCTD | NCI-H358 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1559
GET https://conductscience.org/api/cell-lines/v1/CVCL_1559/papers?page=2